Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
N Martínez-Peinado, N Cortes-Serra… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Chagas disease treatment relies on the lengthy administration of benznidazole
and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the …
and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the …
New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 …
Introduction Chagas disease (CD) affects~ 7 million people worldwide. Benznidazole (BZN)
and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both …
and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both …
Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs under intense transmission pressure
JM Bustamante, AM Padilla, B White… - PLoS neglected …, 2022 - journals.plos.org
Trypanosoma cruzi naturally infects a wide variety of wild and domesticated mammals, in
addition to humans. Depending on the infection dose and other factors, the acute infection …
addition to humans. Depending on the infection dose and other factors, the acute infection …
Investigation of pyrimidine nucleoside analogues as chemical probes to assess compound effects on the proliferation of Trypanosoma cruzi intracellular parasites
ML Sykes, DH Hilko, LI Kung, SA Poulsen… - PLoS Neglected …, 2020 - journals.plos.org
Trypanosoma cruzi parasites utilise de novo pyrimidine biosynthesis to produce DNA and
survive within mammalian host cells. This pathway can be hijacked to assess the replication …
survive within mammalian host cells. This pathway can be hijacked to assess the replication …
Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas' disease drug discovery
AF Fesser, O Braissant, F Olmo, JM Kelly… - PLoS neglected …, 2020 - journals.plos.org
New assay designs are needed to improve the predictive value of the Trypanosoma cruzi in
vitro tests used as part of the Chagas' disease drug development pipeline. Here, we …
vitro tests used as part of the Chagas' disease drug development pipeline. Here, we …
Kinetic Driver of Antibacterial Drugs against Plasmodium falciparum and Implications for Clinical Dosing
E Caton, E Nenortas, RP Bakshi… - Antimicrobial agents and …, 2019 - Am Soc Microbiol
Antibacterial drugs are an important component of malaria therapy. We studied the
interactions of clindamycin, tetracycline, chloramphenicol, and ciprofloxacin against …
interactions of clindamycin, tetracycline, chloramphenicol, and ciprofloxacin against …
Medicinal Chemistry for Neglected Diseases–Malaria, Tuberculosis, Sleeping Sickness, Leishmaniasis and River Blindness
KGaA, GSK and Eisai with activities in the development and distribution of ivermectin,
praziquantel, albendazole and diethylcarbamazine, to name just a few. Third, on top of a …
praziquantel, albendazole and diethylcarbamazine, to name just a few. Third, on top of a …
Every parasite counts?! Improving in vitro assay design for Chagas' disease drug discovery
AF Fesser - 2021 - edoc.unibas.ch
Chagas' disease is caused by the protozoan parasite Trypanosoma cruzi. Symptoms of the
chronic disease occur decades after infection in about 30% of the infected people. The …
chronic disease occur decades after infection in about 30% of the infected people. The …